<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111039</article-id><article-id pub-id-type="publisher-id">ACM-39999</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_48569797.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  儿童阻塞性睡眠呼吸暂停综合征患儿血清IL-35和IL-37水平的研究
  Serum IL-35 and IL-37 Levels in Pediatrics with Obstructive Sleep Apnea Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>栋才</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>程</surname><given-names>涵蓉</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>永莉</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>深圳市龙岗耳鼻咽喉医院，深圳耳鼻咽喉研究所，广东 深圳</addr-line></aff><aff id="aff3"><addr-line>深圳市人民医院呼吸疾病研究所；南方科技大学第一附属医院，暨南大学第二临床医学院，广东 深圳</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>268</fpage><lpage>274</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨儿童OSAS患者血清的IL-35、IL-37的水平。方法：46例新诊断的OSAS患者和35例非呼吸暂停对照者被纳入本研究。人口学资料，既往神经肌肉病、遗传代谢病及药物史，习惯通过标准化问卷获得。所有患者均接受多导睡眠图评估。OSAS组平均年龄6.8 &#177; 3.3(5~9.5)岁。OSAS组中位呼吸暂停低通气指数为12.5 (6.5~21)，中位体重指数为20.5 (18~24.2)。采用ELISA法检测血清IL-35和IL-37水平。结果：OSAS患者血清IL-35和IL-37水平均明显低于健康人。随着OSAS疾病的程度加重，血清IL-35、IL-37水平进一步降低，其差异也具有统计学意义。结论：本研究提示血清IL-35和IL-37可能是OSAS的新的生物标志物，提示调节这两种细胞因子的表达可能为OSAS的治疗提供新的可能靶点。
    Objective: The aim of the present study was to investigate the serum level of IL-35. IL-37 in patients with OSAS. Methods: 46 newly diagnosed pediatrics OSAS patients and 35 non-apneic controls were enrolled in this study. Demographic data, previous history of diseases including metabolic diseases and drugs, and habits were obtained by a standardized questionnaire. All patients underwent polysomnographic evaluation. The mean age was 6.8 &#177; 3.3 (5~9.5) years in the OSAS group. Median apnea-hypopnea index was 12.5 (6.5~21) and median body mass index was 20.5 (18~24.2) in the OSAS group. Cytokine levels in serum were determined using ELISA. Results: The results showed that serums IL-35 and IL-37 levels were significantly decreased in OSAS patients compared with healthy subjects. The cytokine levels correlated inversely with OSAS severity. Conclusion: The study showed that serums IL-35 and IL-37 might be potentially novel biomarkers for OSAS, suggesting that regulating the expression of the two cytokines may provide a new possible target for the treatment of OSAS. 
  
 
</p></abstract><kwd-group><kwd>白细胞介素-35，白细胞介素-37，阻塞性睡眠呼吸暂停综合征，炎症, Interleukin-35</kwd><kwd> Interleukin-37</kwd><kwd> Obstructive Sleep Apnea Syndrome</kwd><kwd> In?ammation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨儿童OSAS患者血清的IL-35、IL-37的水平。方法：46例新诊断的OSAS患者和35例非呼吸暂停对照者被纳入本研究。人口学资料，既往神经肌肉病、遗传代谢病及药物史，习惯通过标准化问卷获得。所有患者均接受多导睡眠图评估。OSAS组平均年龄6.8 &#177; 3.3(5~9.5)岁。OSAS组中位呼吸暂停低通气指数为12.5 (6.5~21)，中位体重指数为20.5 (18~24.2)。采用ELISA法检测血清IL-35和IL-37水平。结果：OSAS患者血清IL-35和IL-37水平均明显低于健康人。随着OSAS疾病的程度加重，血清IL-35、IL-37水平进一步降低，其差异也具有统计学意义。结论：本研究提示血清IL-35和IL-37可能是OSAS的新的生物标志物，提示调节这两种细胞因子的表达可能为OSAS的治疗提供新的可能靶点。</p></sec><sec id="s2"><title>关键词</title><p>白细胞介素-35，白细胞介素-37，阻塞性睡眠呼吸暂停综合征，炎症</p></sec><sec id="s3"><title>Serum IL-35 and IL-37 Levels in Pediatrics with Obstructive Sleep Apnea Syndrome<sup> </sup></title><p>Dongcai Li<sup>1</sup>, Hanrong Cheng<sup>2*</sup>, Yongli Wei<sup>2</sup></p><p><sup>1</sup>Institute of Shenzhen ENT, Longgang ENT Hospital, Shenzhen Guangdong</p><p><sup>2</sup>Institute of Respiratory Diseases, Shenzhen People’s Hospital; The Second Clinical Medical College of Jinan University, 1st Affiliated Hospital of Southern University of Science and Technology, Shenzhen Guangdong</p><p><img src="//html.hanspub.org/file/39-1571859x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/39-1571859x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The aim of the present study was to investigate the serum level of IL-35. IL-37 in patients with OSAS. Methods: 46 newly diagnosed pediatrics OSAS patients and 35 non-apneic controls were enrolled in this study. Demographic data, previous history of diseases including metabolic diseases and drugs, and habits were obtained by a standardized questionnaire. All patients underwent polysomnographic evaluation. The mean age was 6.8 &#177; 3.3 (5~9.5) years in the OSAS group. Median apnea-hypopnea index was 12.5 (6.5~21) and median body mass index was 20.5 (18~24.2) in the OSAS group. Cytokine levels in serum were determined using ELISA. Results: The results showed that serums IL-35 and IL-37 levels were significantly decreased in OSAS patients compared with healthy subjects. The cytokine levels correlated inversely with OSAS severity. Conclusion: The study showed that serums IL-35 and IL-37 might be potentially novel biomarkers for OSAS, suggesting that regulating the expression of the two cytokines may provide a new possible target for the treatment of OSAS.</p><p>Keywords:Interleukin-35, Interleukin-37, Obstructive Sleep Apnea Syndrome, Inﬂammation</p><disp-formula id="hanspub.39999-formula28"><graphic xlink:href="//html.hanspub.org/file/39-1571859x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/39-1571859x8_hanspub.png" /> <img src="//html.hanspub.org/file/39-1571859x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>阻塞性睡眠呼吸暂停综合征(Obstructive sleep apnea syndrome, OSAS)是一种广泛的疾病，其特征是睡眠时反复出现完全或部分上气道阻塞，伴随动脉血氧饱和度下降和睡眠唤醒，导致白天过度嗜睡并引起其他白天症状 [<xref ref-type="bibr" rid="hanspub.39999-ref1">1</xref>]。在儿童，OSAHS的病因是腺样体肥大，扁桃体肥大等方面的因素，并导致炎症和间歇性低氧所致 [<xref ref-type="bibr" rid="hanspub.39999-ref2">2</xref>]。白细胞介素(IL-35)和IL-37是新近发现的免疫抑制细胞因子。IL-35属于IL-12家族，含有IL-12，IL-23和IL-27。它由EB病毒诱导基因3 (Ebi3)和p35 (IL-12a)两个亚基组成 [<xref ref-type="bibr" rid="hanspub.39999-ref3">3</xref>]。在小鼠中，IL-35由Foxp3+CD4+CD25+调节性T细胞(Tregs)分泌，在实验性自身免疫性脑脊髓炎(EAE)中，IL-35和CD138+浆细胞诱导的调节性T细胞群 [<xref ref-type="bibr" rid="hanspub.39999-ref4">4</xref>] 分泌。利用实验数据库挖掘和统计分析方法，Li等人报道IL-35在人体组织中不是组成型表达，但在炎症刺激下是可诱导的 [<xref ref-type="bibr" rid="hanspub.39999-ref5">5</xref>]。IL-37又称IL-1F7，是IL-1家族的一个新成员，具有类似桶状结构的共同特征。IL-37B是五种变异体中最大的同工型，在人类多种正常组织和肿瘤中表达 [<xref ref-type="bibr" rid="hanspub.39999-ref6">6</xref>]。最早在骨髓中发现，中性粒细胞是其合成的主要场所。主要表达于血细胞，呼吸道，胃肠道，以及皮肤角质形成细胞 [<xref ref-type="bibr" rid="hanspub.39999-ref7">7</xref>]。在本研究中，我们旨在调查血浆IL-35和IL-37水平与OSAS严重程度之间的关系，该严重程度由呼吸暂停低通气指数(AHI)确定。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 患者选择</title><p>我们前瞻性评估了2019年2月至2020年2月间在深圳市龙岗耳鼻喉医院睡眠医学中心就诊的患者。这项研究得到了深圳市龙岗耳鼻喉医院伦理委员会的批准，所有患者都签署书面知情同意书。46例新诊断的OSAS患儿和35例年龄匹配的非呼吸暂停对照者被纳入本研究。排除中枢性睡眠呼吸暂停、上气道阻力综合征、肺部疾病、甲状腺功能低下及糖尿病等内分泌疾病、遗传代谢病及神经肌肉病患者。记录年龄，性别，体重指数(BMI)等人口统计学资料。用Epworth嗜睡量表对每位患者进行嗜睡评定。</p></sec><sec id="s6_2"><title>2.2. 多导睡眠图评估</title><p>通过计算机化系统(康迪Compumedics Grael)对所有患者进行全夜诊断性多导睡眠描记术(PSG)，记录脑电图，眼电图，颏下肌电图(EMG)，双侧胫骨前肌电图，心电图，通过电感容积描记法进行的胸壁和腹壁运动，通过鼻压传感器测量，并辅以口腔热敏电阻器，脉冲血氧计，根据美国睡眠医学学会的标准，多导睡眠描记记录在30秒内对睡眠，呼吸和氧合进行评分。儿童睡眠呼吸暂停 [<xref ref-type="bibr" rid="hanspub.39999-ref8">8</xref>] 是一种常见的睡眠呼吸障碍性疾病，是指睡眠过程中频繁发生部分或全部上气道阻塞，口、鼻气流停止持续时间至少为2个呼吸周期以上，分为中枢性(central sleep apnea, CSA)、阻塞性(obstructive sleep apnea, OSA)和混合性三类，其中最常见的是阻塞性睡眠呼吸暂停低通气综合征(obstructive sleep apnea hypopnea syndrome, OSAHS)，儿童OSAHS 是指口鼻气流停止或气流减少30%以上，但存在呼吸运动，引起呼吸暂停和通气不足持续时间至少为2个呼吸周期以上，伴有打鼾、睡眠结构紊乱，低通气事件伴有血氧饱和度下降3%以上，跟据AASM标准，AHI ≥ 1即诊断为儿童OSA。根据OSAS的严重程度分为AHI = 1~5的轻度OSAS组，AHI = 5~10的中度OSAS组和AHI ≥ 10的重度OSAS组 [<xref ref-type="bibr" rid="hanspub.39999-ref9">9</xref>]。</p></sec><sec id="s6_3"><title>2.3. IL-35和IL-37测定</title><p>在进行多导睡眠描记术后的第二天早晨抽取静脉血样本，在室温下以1500 &#215; g离心20分钟，收集血清并在−80℃保存直，直到测定结果。用市售酶联免疫吸附试验(ELISA)试剂盒：IL-37 (Ab 213798)，IL-35 (70-EK135-96)测定血清IL-35和IL-37。所有细胞因子测定均一式两份，并按照制造商的方案进行。</p></sec><sec id="s6_4"><title>2.4. 统计分析</title><p>用GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA)和SPSS19.0 (SPSS Inc., Chicago, IL, USA)进行统计评价。数据以均值&#177;标准误差(SEM)表示。用方差分析评价血清中细胞因子表达的差异。在所有试验中，P &lt; 0.05被认为是显著的。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>本研究纳入了46例OSAS患者和35名对照受试者。表1列出了这两个研究组的基线特征和临床发现：OSAS患者与对照之间的年龄和性别无差异。OSAS组为6.8 &#177; 3.3 (5~9.5)岁，对照组为6.6 &#177; 3.6 (5.5~9.5)岁。81例患者中有46例(男26例，女性20例)被分类为OSAS，35例(20例男性，15例女性)作为对照组。对照组为健康受试者，无睡眠呼吸暂停。OSAS组中，AHI中位数为12.5 (6.5~21)，BMI中位数为20.5 (18~24.2)。根据AHI将患者分为轻度OSAS组(n = 10, 21.7%)，中度OSAS组(n = 20, 43.5%)和重度OSAS组(n = 16, 34.8%)。</p><p>OSAS 患者血清IL-35，IL-37水平降低。OSAS患者血清IL-35和IL-37浓度与健康对照(HC)相比，其差异具有统计学意义(表2)。轻度OSAS与中度OSAS，轻度OSAS与重度OSAS，中度OSAS与重度OSAS之间，随着OSAS疾病的程度加重，血清IL-35，IL-37水平进一步降低，其差异也具有统计学意义(P &lt; 0.05) (表2)。</p></sec><sec id="s8"><title>4. 讨论</title><p>阻塞性睡眠呼吸暂停综合征(obstructive sleep apnea syndrome, OSAS)是指睡眠时出现上气道咽腔水平反复的塌陷为主要特征，主要表现为睡眠时打鼾并伴有呼吸暂停，夜间反复发生低氧血症、高碳酸血</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of OSAS and control grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >患者基本信息</th><th align="center" valign="middle" >正常对照组</th><th align="center" valign="middle" >OSAS组</th><th align="center" valign="middle" >P 值</th></tr></thead><tr><td align="center" valign="middle" >例数</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >性别(F/M)</td><td align="center" valign="middle" >15/20</td><td align="center" valign="middle" >20/26</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >6.6 &#177; 3.6 (5.5~9.5)</td><td align="center" valign="middle" >6.8 &#177; 3.3 (5~9.5)</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >AHI组别例数</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0~1</td><td align="center" valign="middle" >35 (100%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1~5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10 (21.7%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >5~10</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20 (43.5%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;10</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >16 (34.8%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;24.9</td><td align="center" valign="middle" >19.6 (17~23.2)</td><td align="center" valign="middle" >20.5 (18~24.2)</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >共患病</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >糖尿病及甲状腺疾病</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >神经肌肉病</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >遗传代谢病</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >ns</td></tr></tbody></table></table-wrap><p>表1. OSAS与对照组的比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Serum levels of IL-35 and IL-37 in OSAS and control group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >正常对照组</th><th align="center" valign="middle" >轻度OSAS</th><th align="center" valign="middle" >中度OSAS</th><th align="center" valign="middle" >重度OSAS</th></tr></thead><tr><td align="center" valign="middle" >IL-35 (ng/mL)</td><td align="center" valign="middle" >1866.96 &#177; 209.43****</td><td align="center" valign="middle" >956.17 &#177; 219.38***</td><td align="center" valign="middle" >465.26 &#177; 160.36**</td><td align="center" valign="middle" >216.33&#177; 36.26*</td></tr><tr><td align="center" valign="middle" >IL-37 (ng/mL)</td><td align="center" valign="middle" >2189.68 &#177; 261.24^^^^</td><td align="center" valign="middle" >1105.67 &#177; 232.82^^^</td><td align="center" valign="middle" >502.66 &#177; 138.56^^</td><td align="center" valign="middle" >186.89 &#177; 36.50^</td></tr></tbody></table></table-wrap><p>表2. OSAS与对照组血清IL-35和IL-37水平</p><p>各组之间IL-35水平比较，P &lt; 0.05；各组之间IL-37水平比较，P &lt; 0.05。</p><p>症和睡眠结构紊乱，可造成多脏器损害 [<xref ref-type="bibr" rid="hanspub.39999-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39999-ref10">10</xref>]。由于呼吸暂停引起反复发作的夜间低氧和高碳酸血症，可导致高血压、冠心病、心律失常、糖尿病等，而心、脑血管的合并症最为常见和严重，甚至出现夜间猝死。目前肥胖的发生率增加，因此，OSAS的发生率也随之升高。众所周知，多导睡眠图是其标准诊断，然而它具有一定的局限性，包括成本、有限可用性及需要患者的积极配合，因此炎症因子及代谢指标在评估OSAS并发症中起到了重要的作用 [<xref ref-type="bibr" rid="hanspub.39999-ref11">11</xref>]。早期的预测因子为临床提供依据，早发现，早治疗，积极干预，提高患者的生活质量，减少发生不良事件具有非常重要的意义。</p><p>OSAS在儿童中表现为行为异常，注意力障碍，白天过度嗜睡、多动，严重者可引起肺心病，生长发育迟缓，对儿童的身体健康、智力发育和生长带来极大影响，严重威胁儿童健康。OSAHS的病因包括腺样体肥大，扁桃体肥大、鼻中隔偏曲、小下颌、鼻甲肥大、鼻息肉等解剖方面的因素，引起炎症因子TNF-a、IL-6、IL-10、CRP过度释放等相关，主要是间歇性低氧导致 [<xref ref-type="bibr" rid="hanspub.39999-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.39999-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.39999-ref14">14</xref>]。</p><p>到目前为止，C反应蛋白(CRP)和肿瘤坏死因子等临床标志物已被报道与OSAS有关 [<xref ref-type="bibr" rid="hanspub.39999-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.39999-ref16">16</xref>]。Mehra等人已经证明OSAS患者与对照组相比IL-6水平升高 [<xref ref-type="bibr" rid="hanspub.39999-ref17">17</xref>]。虽然有一些有说服力的结果，但介体水平的升高被认为是OSAS患者缺氧和肥胖的继发性因素。Nural等人报道了持续气道正压(CPAP)治疗后血清CRP水平显著降低 [<xref ref-type="bibr" rid="hanspub.39999-ref18">18</xref>]。在最近的一项研究中，作者发现在调整年龄、腰围和吸烟后，AHI和IL-6水平之间没有明显的相关性 [<xref ref-type="bibr" rid="hanspub.39999-ref19">19</xref>]。Yokoe在Al的报告中也有类似的发现 [<xref ref-type="bibr" rid="hanspub.39999-ref20">20</xref>]。除此之外，Vgontzas等人 [<xref ref-type="bibr" rid="hanspub.39999-ref21">21</xref>] 发现OSAS患者的IL-6和TNF-a水平高于健康受试者。IL-37被认为具有转位到细胞核的功能，并能在细胞内外重新分布。IL-37向细胞内转移可能是血清中IL-37含量下降的原因。研究表明，血清IL-35和IL-37水平降低可能代表体内抗炎活性不足，并有望作为监测OSAS疾病严重程度的新生物标志物。在本研究中，我们首次证实OSAS患者血清IL-35和IL-37水平显著低于健康对照组，并且随着OSAS疾病的程度加重，血清IL-35，IL-37水平进一步降低，其差异也具有统计学意义。</p><p>IL-35和IL-37的作用机制目前尚不清楚。IL-35参与神经系统、消化系统、骨关节系统和呼吸系统的炎症性疾病。Zandian等人证明IL-35通过阻止自身侵袭性T细胞的发展而具有抑制脱髓鞘的作用 [<xref ref-type="bibr" rid="hanspub.39999-ref22">22</xref>]。Kochetkova等人提示外源性IL-35可抑制CD4+T细胞，Th1和Th17细胞的活性，抑制胶原诱导性关节炎的炎症 [<xref ref-type="bibr" rid="hanspub.39999-ref23">23</xref>]。同时，提示IL-35可以帮助呼吸系统从炎症中恢复 [<xref ref-type="bibr" rid="hanspub.39999-ref24">24</xref>]。Wirtz等人最近证实IL-35能显著抑制Th1和Th17细胞的增殖，减少实验性结肠炎的发生，保护小肠免受免疫反应的影响 [<xref ref-type="bibr" rid="hanspub.39999-ref25">25</xref>]。IL-35的一个亚单位Ebi3在EBV转化的B淋巴细胞和组织中广泛表达，如扁桃体和脾脏 [<xref ref-type="bibr" rid="hanspub.39999-ref26">26</xref>]。Ebi3可负性调节IL-17，IL-22和Th17转录因子ROR T，发挥抗炎保护性免疫 [<xref ref-type="bibr" rid="hanspub.39999-ref27">27</xref>]。IL-12亚单位p35可导致小鼠疱疹基质性角膜炎(HSK)的进展，与IL-12p40无关 [<xref ref-type="bibr" rid="hanspub.39999-ref28">28</xref>]。IL-35的两个亚单位确实具有自身调节免疫和炎症过程的能力。当它们结合在一起形成异二聚体时，p35亚基可能起配体的作用，而另一个亚基EBI3可能主要发挥其免疫功能 [<xref ref-type="bibr" rid="hanspub.39999-ref29">29</xref>]。到目前为止，IL-35的信号转导途径尚不清楚。同时，研究证实IL-35通过独特的受体链异源二聚体IL-12 R2和gp130或每条链的同源二聚体进行信号传递 [<xref ref-type="bibr" rid="hanspub.39999-ref30">30</xref>]。通过IL-35受体的信号传导需要转录因子STAT1和STAT4，STAT1和STAT4形成独特的异源二聚体，结合到编码IL-12亚基p35和EBI3的基因启动子中的不同位点。IL-35可直接抑制Teff细胞增殖，将原始T细胞转化为产生IL-35的iTr35细胞，抑制Th17细胞的发育，并介导IL-10的产生。同样，IL-37是炎症、自身免疫和其他免疫学疾病的细胞因子。IL-37蛋白在类风湿性关节炎患者的滑膜细胞中高表达，但在健康人滑膜细胞中表达低水平 [<xref ref-type="bibr" rid="hanspub.39999-ref31">31</xref>]。银屑病患者的皮损和克罗恩病皮损的巨噬细胞中IL-37的表达也显著增加 [<xref ref-type="bibr" rid="hanspub.39999-ref27">27</xref>]。IL-37是作为前蛋白合成的，在刺激后，它被加工成成熟形式 [<xref ref-type="bibr" rid="hanspub.39999-ref32">32</xref>]。脂多糖(LPS)与其他炎症刺激物和细胞因子一起激活caspase-1，被认为是负责IL-1家族前体成熟的主要裂解酶。IL-37具有抗菌，抗病毒，中和内毒素，抗肿瘤，免疫调节等广谱功能，对微生物具有普遍的杀灭作用。其作用机制主要是通过改变细菌细胞的通透性。它还具有提高IL-8等几种细胞因子的产生以扩大获得性免疫功能的能力 [<xref ref-type="bibr" rid="hanspub.39999-ref33">33</xref>]。对小鼠模型的研究已经得出IL-37下调炎症的结果。TLR、肿瘤坏死因子(TNF)等细胞因子可诱导炎性细胞因子的产生。诺德等人报道IL-37减弱上述过程，从而发挥抗炎作用 [<xref ref-type="bibr" rid="hanspub.39999-ref31">31</xref>]。</p><p>本研究存在潜在的局限性。第一，样本量相对较小。尽管有这样的发现，显然需要进行大规模的前瞻性研究来确定OSAS及其亚组的IL-35、IL-37水平。其次，我们的研究不包含CPAP治疗后的受试者的随访记录，应进一步研究IL-35和IL-37的作用机制，以使其在今后的研究中得到应用。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，对OSAS患者炎症和氧化应激状态的进一步研究将有助于全面、深入地认识OSAS的发病机制。尽管各种研究证实炎症因子及代谢指标有助于OSAS的严重性的预测，但更准确、更理想的指标有待于进一步发现及临床验证应用。炎症因子和阻塞性睡眠呼吸暂停低通气综合征严重程度的相关性，提出了可能的新的检验指标，为深入探讨OSAHS的发病机制、临床评估、预后及疗效评估提供一定的参考价值。</p></sec><sec id="s10"><title>文章引用</title><p>李栋才,程涵蓉,魏永莉. 儿童阻塞性睡眠呼吸暂停综合征患儿血清IL-35和IL-37水平的研究Serum IL-35 and IL-37 Levels in Pediatrics with Obstructive Sleep Apnea Syndrome[J]. 临床医学进展, 2021, 11(01): 268-274. https://doi.org/10.12677/ACM.2021.111039</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39999-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Taioufis, C., Thornopoulos, K., Dimitriadis, K., Anastasia, A., Dimitris, T., Christodoulos, S., et al. (2007) The Incremental Effect of Obstructive Sleep Apnoea Syndrome on Arterial Stiffness in Newly Diagnosed Essential Hypertensive Subjects. Journal of Hypertension, 26, 141-146. &lt;br&gt;https://doi.org/10.1097/HJH.0b013e32801092c1</mixed-citation></ref><ref id="hanspub.39999-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bhushan, B., Guleria, R., Misra, A., Pandey, R.M., Luthra, K., Vikram, N.K., et al. (2009) Obstructive Sleep Apnoea Correlates with C-Reactive Protein in Obese Asian Indians. Nutrition, Metabolism and Cardiovascular Diseases, 19, 184-189. &lt;br&gt;https://doi.org/10.1016/j.numecd.2008.06.008</mixed-citation></ref><ref id="hanspub.39999-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., et al. (2007) The Inhibitory Cytokine IL-35 Contributes to Regulatory T-Cell Function. Nature, 450, 566-569. &lt;br&gt;https://doi.org/10.1038/nature06306</mixed-citation></ref><ref id="hanspub.39999-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chaturvedi, V., Collison, L.W., Guy, C.S., Workman, C.J. and Vignali, D.A.A. (2011) Cutting Edge: Human Regulatory T Cells Require IL-35 to Mediate Suppression and Infectious Tolerance. Journal of Immunology, 186, 6661-6666.  
&lt;br&gt;https://doi.org/10.4049/jimmunol.1100315</mixed-citation></ref><ref id="hanspub.39999-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Mai, J., Virtue, A., Yin, Y., Gong, R., Sha, X., et al. (2012) IL-35 Is a Novel Responsive Anti-Inflammatory Cytokine—A New System of Categorizing Anti-Inflammatory Cytokines. PLoS ONE, 7, e33628. 
&lt;br&gt;https://doi.org/10.1371/journal.pone.0033628</mixed-citation></ref><ref id="hanspub.39999-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lee, Y.K. and Mazmanian, S.K. (2010) Has the Microbiota Played a Critical Role in the Evolution of the Adaptive Immune System? Science, 330, 1768-1773. &lt;br&gt;https://doi.org/10.1126/science.1195568</mixed-citation></ref><ref id="hanspub.39999-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chen, P. and Fang, S. (2004) The Expression of Human Antimicrobial Peptide LL-37 in the Human Nasal Mucosa. The American Journal of Rhinology, 18, 381-385. &lt;br&gt;https://doi.org/10.1177/194589240401800608</mixed-citation></ref><ref id="hanspub.39999-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Guilleminault, C., Tilkian, A. and Dement, W.C. (1976) The Sleep Apnea Syndromes. Annual Review of Medicine, 27, 465-484. &lt;br&gt;https://doi.org/10.1146/annurev.me.27.020176.002341</mixed-citation></ref><ref id="hanspub.39999-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Marcus, C.L., Brooks, L.J., Draper, K.A., Gozal, D., Halbower, A.C., Jones, J., et al. (2012) Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome, Pediatrics, 130, 576-584.  
&lt;br&gt;https://doi.org/10.1542/peds.2012-1671</mixed-citation></ref><ref id="hanspub.39999-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会呼吸病学分会睡眠呼吸障碍学组. 阻塞性睡眠呼吸暂停低通气合征诊治指南(2011年修订版)[J].中华结核和呼吸杂志, 2012, 35(1): 9-12.</mixed-citation></ref><ref id="hanspub.39999-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">De Luca Canto, G., Pacheco-Pereira, C., Aydinoz, S., Major, P.W., Flores Mir, C. and Gozal, D. (2014) Biomarkers Associated with Obstructive Sleep Apnea: A Scoping Review. Sleep Medicine Reviews, 23, 28-45. 
&lt;br&gt;https://doi.org/10.1016/j.smrv.2014.11.004</mixed-citation></ref><ref id="hanspub.39999-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Katz, E.S. and D’Ambrosio, C.M. (2010) Pediatric Obstructive Sleep Apnea Syndrome. Clinics in Chest Medicine, 31, 221-234. &lt;br&gt;https://doi.org/10.1016/j.ccm.2010.02.002</mixed-citation></ref><ref id="hanspub.39999-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Farber, J.M. (2002) Clinical Practice Guideline: Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome. Pediatrics, 110, 1255-1257. &lt;br&gt;https://doi.org/10.1542/peds.110.6.1255-a</mixed-citation></ref><ref id="hanspub.39999-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ryan, S., Taylor, C.T. and McNicholas, W.T. (2009) Systemic Inflammation: A Key Factor in the Pathogenesis of Cardiovascular Complications in Obstructive Sleep Apnoea Syndrome. Thorax, 64, 631-636.</mixed-citation></ref><ref id="hanspub.39999-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Minoguchi, K., Tazaki, T., Yokoe, T., Minoguchi, H., Watanabe, Y., Yamamoto, M., et al. (2004) Elevated Production of Tumor Necrosis Factor-Alpha by Monocytes in Patients with Obstructive Sleep Apnea Syndrome. Chest, 126, 1473-1479. &lt;br&gt;https://doi.org/10.1378/chest.126.5.1473</mixed-citation></ref><ref id="hanspub.39999-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lui, M.M., Lam, J.C., Mak, H.K., Xu, A., Ooi, C., Lam, D.C., et al. (2009) C-Reactive Protein Is Associated with Obstructive Sleep Apnea Independent of Visceral Obesity. Chest, 135, 950-956. &lt;br&gt;https://doi.org/10.1378/chest.08-1798</mixed-citation></ref><ref id="hanspub.39999-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Mehra, R., Storfer-Isser, A., Kirchner, H.L., Johnson, N., Jenny, N., Tracy, R.P., et al. (2006) Soluble Interleukin 6 Receptor: A Novel Marker of Moderate to Severe Sleep-Related Breathing Disorder. Archives of Internal Medicine, 166, 1725-1731. &lt;br&gt;https://doi.org/10.1001/archinte.166.16.1725</mixed-citation></ref><ref id="hanspub.39999-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nural, S., Gunay, E., Halici, B., Celik, S. and Unlu, M. (2013) Inﬂammatory Processes and Effects of Continuous Positive Airway Pressure (CPAP) in Overlap Syndrome. Inﬂammation, 36, 66-74.  
&lt;br&gt;https://doi.org/10.1007/s10753-012-9520-z</mixed-citation></ref><ref id="hanspub.39999-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Svensson, M., Venge, P., Janson, C. and Lindberg, E. (2012) Relationship between Sleep-Disordered Breathing and Markers of Systemic Inﬂammation in Women from the General Population. Journal of Sleep Research, 21, 147-154.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2869.2011.00946.x</mixed-citation></ref><ref id="hanspub.39999-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yokoe, T., Minoguchi, K., Matsuo, H., Oda, N., Minoguchi, H., Yoshino, G., et al. (2003) Elevated Levels of C-Reactive Protein Andinterleukin-6 in Patients with Obstructive Sleep Apnea Syndrome Are Decreased by Nasal Continuous Positive Airway Pressure. Circulation, 107, 1129-1134.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.0000052627.99976.18</mixed-citation></ref><ref id="hanspub.39999-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Vgontzas, A.N., Papanicolaou, D.A., Bixler, E.O., Kales, A., Tyson, K. and Chrousos, G.P. (1997) Elevation of Plasma Cytokines in Disorders of Excessive Daytime Sleepiness: Role of Sleep Disturbance and Obesity. The Journal of Clinical Endocrinology and Metabolism, 82, 1313-1316. &lt;br&gt;https://doi.org/10.1210/jcem.82.5.3950</mixed-citation></ref><ref id="hanspub.39999-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zandian, M., Mott, K.R., Allen, S.J., Dumitrascu, O., Kuo, J.Z. and Ghiasi, H. (2011) Use of Cytokine Immunotherapy to Block CNS Demyelination Induced by a Recombinant HSV-1 Expressing IL-2. Gene Therapy, 18, 734-742. 
&lt;br&gt;https://doi.org/10.1038/gt.2011.32</mixed-citation></ref><ref id="hanspub.39999-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kochetkova, I., Golden, S., Holderness, K., Callis, G. and Pascual, D.W. (2010) IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10. Journal of Immunology, 184, 7144-7153. &lt;br&gt;https://doi.org/10.4049/jimmunol.0902739</mixed-citation></ref><ref id="hanspub.39999-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Whitehead, G.S., Wilson, R.H., Nakano, K., Burch, L.H., Nakano, H. and Cook, D.N. (2012) IL-35 Production by Inducible Costimulator (ICOS)-Positive Regulatory T Cells Reverses Established IL-17-Dependent Allergic Airways Disease. Journal of Allergy and Clinical Immunology, 129, 207-215.E5. &lt;br&gt;https://doi.org/10.1016/j.jaci.2011.08.009</mixed-citation></ref><ref id="hanspub.39999-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Wirtz, S., Billmeier, U., McHedlidze, T., Blumberg, R.S. and Neurath, M.F. (2011) Interleukin-35 Mediates Mucosal Immune Responses That Protect against T-Cell-Dependent Colitis. Gastroenterology, 141, 1875-1886. 
&lt;br&gt;https://doi.org/10.1053/j.gastro.2011.07.040</mixed-citation></ref><ref id="hanspub.39999-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Devergne, O., Birkenbach, M. and Kieff, E. (1997) Epstein-Barr Virus-Induced Gene 3 and the p35 Subunit of Interleukin 12 form a Novel Heterodimeric Hematopoietin. Proceedings of the National Academy of Sciences of the United States of America, 94, 12041-12046. &lt;br&gt;https://doi.org/10.1073/pnas.94.22.12041</mixed-citation></ref><ref id="hanspub.39999-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., Yang, M., Htut, T.M., Ouyang, X., Hanidu, A., Li, X., et al. (2008) Epstein-Barr Virus-Induced Gene 3 Negatively Regulates IL-17, IL-22 and ROR𝛾t. European Journal of Immunology, 38, 1204-1214. 
&lt;br&gt;https://doi.org/10.1002/eji.200838145</mixed-citation></ref><ref id="hanspub.39999-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Frank, G.M., Divito, S.J., Maker, D.M., Xu, M. and Hendricks, R.L. (2010) A Novel P40-Independent Function of IL-12P35 Is Required for Progression and Maintenance of Herpes Stromal Keratitis. Investigative Ophthalmology and Visual Science, 51, 3591-3598. &lt;br&gt;https://doi.org/10.1167/iovs.09-4368</mixed-citation></ref><ref id="hanspub.39999-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ye, S., Wu, J., Zhou, L., Lv, Z., Xie, H. and Zheng, S. (2013) Interleukin-35: The Future of Hyperimmune-Related Diseases? Journal of Interferon and Cytokine Research, 33, 285-291. &lt;br&gt;https://doi.org/10.1089/jir.2012.0086</mixed-citation></ref><ref id="hanspub.39999-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Collison, L.W., Delgoffe, G.M., Guy, C.S., Vignali, K.M., Chaturvedi, V., Fairweather, D.L., et al. (2012) The Composition and Signaling of the IL-35 Receptor Are Unconventional. Nature Immunology, 13, 290-299.  
&lt;br&gt;https://doi.org/10.1038/ni.2227</mixed-citation></ref><ref id="hanspub.39999-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Nold, M.F., Nold-Petry, C.A., Zepp, J.A., Palmer, B.E., Bufler, P. and Dinarello, C.A. (2010) IL-37 Is a Fundamental Inhibitor of Innate Immunity. Nature Immunology, 11, 1014-1022. &lt;br&gt;https://doi.org/10.1038/ni.1944</mixed-citation></ref><ref id="hanspub.39999-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., Mangelberger, D., et al. (2011) IL-37: A New Anti-Inflammatory Cytokine of the IL-1 Family. European Cytokine Network, 22, 127-147.  
&lt;br&gt;https://www.jle.com/10.1684/ecn.2011.0288</mixed-citation></ref><ref id="hanspub.39999-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">de Smet, K. and Contreras, R. (2005) Human Antimicrobial Peptides: Defensins, Cathelicidins and Histatins. Biotechnology Letters, 27, 1337-1347. &lt;br&gt;https://doi.org/10.1007/s10529-005-0936-5</mixed-citation></ref></ref-list></back></article>